GLP-1 agonists are being used in combination with basal insulin (Dungan & DeSantis, 2016), although this is not an FDA-approved indication (see rxlist.com) they should not be used as a substitute for basal insulin, as this has been found to result in a decline in glycemic control)(Dungan & DeSantis, 2016) Clinical trials indicate it can reduce HbA1c by ~0.8% Undergoes renal clearance, with dosage reduction needed if creatinine clearance falls to 1.5
Early reports indicate that some pharmacies have attempted to route Bridge claims through standard Part D plans, resulting in denials
States with Comprehensive Coverage: Some progressive states have expanded Medicaid formularies to include weight-loss medications, recognizing obesity as a serious chronic disease: California: Covers multiple GLP-1 medications for weight loss with prior authorization New York: Expanded coverage in recent years for eligible beneficiaries Washington: Includes GLP-1 medications in state Medicaid formulary Massachusetts: Offers coverage with specific eligibility criteria States with Limited or No Coverage: Many states maintain restrictive policies, either excluding weight-loss medications entirely or imposing such stringent prior authorization requirements that few patients gain approval: Texas: Generally excludes weight-loss medications from Medicaid coverage Florida: Limited coverage with extensive restrictions Ohio: Restrictive prior authorization and quantity limits Multiple Southern states: No coverage for weight-loss indications Coverage for Diabetes: Nearly all state Medicaid programs cover GLP-1 medications when prescribed for type 2 diabetes, though prior authorization requirements typically apply
Should you need mixing instructions, they can be found here This product is intended for research and medical purposes only.
N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial
